Skip to main content
NCBI home page
The Journal of Experimental Medicine logoLink to The Journal of Experimental Medicine
. 1989 Feb 1;169(2):457–467. doi: 10.1084/jem.169.2.457

FBL-reactive CD8+ cytotoxic and CD4+ helper T lymphocytes recognize distinct Friend murine leukemia virus-encoded antigens

PMCID: PMC2189204  PMID: 2562982

Abstract

Immunization of C57BL/6 (B6) mice with FBL, a Friend murine leukemia virus (F-MuLV), induces both tumor-specific cytolytic CD8+ (CTL) and lymphokine-producing CD4+ Th that are effective in adoptive therapy of B6 mice bearing disseminated FBL leukemia. The current study evaluated the F-MuLV antigenic determinants expressed on FBL that are recognized by FBL-reactive CD8+ and CD4+ T cells. To identify the specificity of the FBL-reactive CD8+ CTL, Fisher rat embryo fibroblast (FRE) cells transfected with plasmids encoding F-MuLV gag or envelope (env) gene products plus the class I-restricting element Db were utilized. FBL- reactive CTL recognized FRE target cells transfected with the F-MuLV gag-encoded gene products, but failed to recognize targets expressing F- MuLV env. Attempts to generate env-specific CD8+ CTL by immunization with a recombinant vaccinia virus containing an inserted F-MuLV env gene were unsuccessful, despite the generation of a cytolytic response to vaccinia epitopes, implying that B6 mice fail to generate CD8+ CTL to env determinants. By contrast, CD4+ Th clones recognized FRE target cells transfected with env and not gag genes, and immunization with the recombinant vaccinia virus induced an env-specific CD4+ T cell response. These data show that in a Friend retrovirus-induced tumor model in which tumor rejection can be mediated by either CTL or Th, antigens derived from discrete retroviral proteins are predominantly responsible for activation of each T cell subset.

Full Text

The Full Text of this article is available as a PDF (786.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Berendt M. J., North R. J. T-cell-mediated suppression of anti-tumor immunity. An explanation for progressive growth of an immunogenic tumor. J Exp Med. 1980 Jan 1;151(1):69–80. doi: 10.1084/jem.151.1.69. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bookman M. A., Swerdlow R., Matis L. A. Adoptive chemoimmunotherapy of murine leukemia with helper T lymphocyte clones. J Immunol. 1987 Nov 1;139(9):3166–3170. [PubMed] [Google Scholar]
  3. Braciale T. J., Morrison L. A., Sweetser M. T., Sambrook J., Gething M. J., Braciale V. L. Antigen presentation pathways to class I and class II MHC-restricted T lymphocytes. Immunol Rev. 1987 Aug;98:95–114. doi: 10.1111/j.1600-065x.1987.tb00521.x. [DOI] [PubMed] [Google Scholar]
  4. Buus S., Sette A., Grey H. M. The interaction between protein-derived immunogenic peptides and Ia. Immunol Rev. 1987 Aug;98:115–141. doi: 10.1111/j.1600-065x.1987.tb00522.x. [DOI] [PubMed] [Google Scholar]
  5. Cheever M. A., Greenberg P. D., Fefer A. Specificity of adoptive chemoimmunotherapy of established syngeneic tumors. J Immunol. 1980 Aug;125(2):711–714. [PubMed] [Google Scholar]
  6. Cheever M. A., Thompson D. B., Klarnet J. P., Greenberg P. D. Antigen-driven long term-cultured T cells proliferate in vivo, distribute widely, mediate specific tumor therapy, and persist long-term as functional memory T cells. J Exp Med. 1986 May 1;163(5):1100–1112. doi: 10.1084/jem.163.5.1100. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Chesebro B., Wehrly K., Cloyd M., Britt W., Portis J., Collins J., Nishio J. Characterization of mouse monoclonal antibodies specific for Friend murine leukemia virus-induced erythroleukemia cells: friend-specific and FMR-specific antigens. Virology. 1981 Jul 15;112(1):131–144. doi: 10.1016/0042-6822(81)90619-x. [DOI] [PubMed] [Google Scholar]
  8. Dailey M. O., Pillemer E., Weissman I. L. Protection against syngeneic lymphoma by a long-lived cytotoxic T-cell clone. Proc Natl Acad Sci U S A. 1982 Sep;79(17):5384–5387. doi: 10.1073/pnas.79.17.5384. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Earl P. L., Moss B., Morrison R. P., Wehrly K., Nishio J., Chesebro B. T-lymphocyte priming and protection against Friend leukemia by vaccinia-retrovirus env gene recombinant. Science. 1986 Nov 7;234(4777):728–731. doi: 10.1126/science.3490689. [DOI] [PubMed] [Google Scholar]
  10. FRIEND C. Cell-free transmission in adult Swiss mice of a disease having the character of a leukemia. J Exp Med. 1957 Apr 1;105(4):307–318. doi: 10.1084/jem.105.4.307. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Fernandez-Cruz E., Woda B. A., Feldman J. D. Elimination of syngeneic sarcomas in rats by a subset of T lymphocytes. J Exp Med. 1980 Oct 1;152(4):823–841. doi: 10.1084/jem.152.4.823. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Fogler W. E., Fidler I. J. Nonselective destruction of murine neoplastic cells by syngeneic tumoricidal macrophages. Cancer Res. 1985 Jan;45(1):14–18. [PubMed] [Google Scholar]
  13. Gammon G., Shastri N., Cogswell J., Wilbur S., Sadegh-Nasseri S., Krzych U., Miller A., Sercarz E. The choice of T-cell epitopes utilized on a protein antigen depends on multiple factors distant from, as well as at the determinant site. Immunol Rev. 1987 Aug;98:53–73. doi: 10.1111/j.1600-065x.1987.tb00519.x. [DOI] [PubMed] [Google Scholar]
  14. Germain R. N. Immunology. The ins and outs of antigen processing and presentation. Nature. 1986 Aug 21;322(6081):687–689. doi: 10.1038/322687a0. [DOI] [PubMed] [Google Scholar]
  15. Gomard E., Duprez V., Reme T., Colombani M. J., Levy J. P. Exclusive involvement of H-2Db or H-2Kd product in the interaction between T-killer lymphocytes and syngeneic H-2b or H-2d viral lymphomas. J Exp Med. 1977 Oct 1;146(4):909–922. doi: 10.1084/jem.146.4.909. [DOI] [PMC free article] [PubMed] [Google Scholar]
  16. Greenberg P. D., Cheever M. A., Fefer A. Eradication of disseminated murine leukemia by chemoimmunotherapy with cyclophosphamide and adoptively transferred immune syngeneic Lyt-1+2- lymphocytes. J Exp Med. 1981 Sep 1;154(3):952–963. doi: 10.1084/jem.154.3.952. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Greenberg P. D., Cheever M. A., Fefer A. H-2 restriction of adoptive immunotherapy of advanced tumors. J Immunol. 1981 Jun;126(6):2100–2103. [PubMed] [Google Scholar]
  18. Greenberg P. D., Kern D. E., Cheever M. A. Therapy of disseminated murine leukemia with cyclophosphamide and immune Lyt-1+,2- T cells. Tumor eradication does not require participation of cytotoxic T cells. J Exp Med. 1985 May 1;161(5):1122–1134. doi: 10.1084/jem.161.5.1122. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Greenberg P. D. Therapy of murine leukemia with cyclophosphamide and immune Lyt-2+ cells: cytolytic T cells can mediate eradication of disseminated leukemia. J Immunol. 1986 Mar 1;136(5):1917–1922. [PubMed] [Google Scholar]
  20. Hoang-Xuan M., Charron D., Zilber M. T., Levy D. Biochemical characterization of class II bovine major histocompatibility complex antigens using cross-species reactive antibodies. Immunogenetics. 1982;15(6):621–624. doi: 10.1007/BF00347058. [DOI] [PubMed] [Google Scholar]
  21. Holt C. A., Osorio K., Lilly F. Friend virus-specific cytotoxic T lymphocytes recognize both gag and env gene-encoded specificities. J Exp Med. 1986 Jul 1;164(1):211–226. doi: 10.1084/jem.164.1.211. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Kern D. E., Klarnet J. P., Jensen M. C., Greenberg P. D. Requirement for recognition of class II molecules and processed tumor antigen for optimal generation of syngeneic tumor-specific class I-restricted CTL. J Immunol. 1986 Jun 1;136(11):4303–4310. [PubMed] [Google Scholar]
  23. Kern D. E., Lachmann L. B., Greenberg P. D. Lyt-2+ cells. Requirements for concanavalin A-induced proliferation and interleukin 2 production. J Immunol. 1987 Nov 1;139(9):2880–2887. [PubMed] [Google Scholar]
  24. Kern D. E., Peace D. J., Klarnet J. P., Cheever M. A., Greenberg P. D. Il-4 is an endogenous T cell growth factor during the immune response to a syngeneic retrovirus-induced tumor. J Immunol. 1988 Oct 15;141(8):2824–2830. [PubMed] [Google Scholar]
  25. Klarnet J. P., Matis L. A., Kern D. E., Mizuno M. T., Peace D. J., Thompson J. A., Greenberg P. D., Cheever M. A. Antigen-driven T cell clones can proliferate in vivo, eradicate disseminated leukemia, and provide specific immunologic memory. J Immunol. 1987 Jun 1;138(11):4012–4017. [PubMed] [Google Scholar]
  26. Leclerc J. C., Cantor H. T cell-mediated immunity to oncornavirus-induced tumors. I. Ly phenotype of precursor and effector cytolytic T lymphocytes. J Immunol. 1980 Feb;124(2):846–850. [PubMed] [Google Scholar]
  27. Lukacher A. E., Braciale V. L., Braciale T. J. In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med. 1984 Sep 1;160(3):814–826. doi: 10.1084/jem.160.3.814. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Marrack P., Kappler J. T cells can distinguish between allogeneic major histocompatibility complex products on different cell types. Nature. 1988 Apr 28;332(6167):840–843. doi: 10.1038/332840a0. [DOI] [PubMed] [Google Scholar]
  29. Matis L. A., Ruscetti S. K., Longo D. L., Jacobson S., Brown E. J., Zinn S., Kruisbeek A. M. Distinct proliferative T cell clonotypes are generated in response to a murine retrovirus-induced syngeneic T cell leukemia: viral gp70 antigen-specific MT4+ clones and Lyt-2+ cytolytic clones which recognize a tumor-specific cell surface antigen. J Immunol. 1985 Jul;135(1):703–713. [PubMed] [Google Scholar]
  30. Mills C. D., North R. J. Expression of passively transferred immunity against an established tumor depends on generation of cytolytic T cells in recipient. Inhibition by suppressor T cells. J Exp Med. 1983 May 1;157(5):1448–1460. doi: 10.1084/jem.157.5.1448. [DOI] [PMC free article] [PubMed] [Google Scholar]
  31. Moss B., Flexner C. Vaccinia virus expression vectors. Annu Rev Immunol. 1987;5:305–324. doi: 10.1146/annurev.iy.05.040187.001513. [DOI] [PubMed] [Google Scholar]
  32. Nabholz M., MacDonald H. R. Cytolytic T lymphocytes. Annu Rev Immunol. 1983;1:273–306. doi: 10.1146/annurev.iy.01.040183.001421. [DOI] [PubMed] [Google Scholar]
  33. Nowinski R. C., Emery S., Ledbetter J. Identification of an FMR cell surface antigen associated with murine leukemia virus-infected cells. J Virol. 1978 Jun;26(3):805–812. doi: 10.1128/jvi.26.3.805-812.1978. [DOI] [PMC free article] [PubMed] [Google Scholar]
  34. Plata F., Langlade-Demoyen P., Abastado J. P., Berbar T., Kourilsky P. Retrovirus antigens recognized by cytolytic T lymphocytes activate tumor rejection in vivo. Cell. 1987 Jan 30;48(2):231–240. doi: 10.1016/0092-8674(87)90426-0. [DOI] [PubMed] [Google Scholar]
  35. Quinnan G. V., Jr, Kirmani N., Rook A. H., Manischewitz J. F., Jackson L., Moreschi G., Santos G. W., Saral R., Burns W. H. Cytotoxic t cells in cytomegalovirus infection: HLA-restricted T-lymphocyte and non-T-lymphocyte cytotoxic responses correlate with recovery from cytomegalovirus infection in bone-marrow-transplant recipients. N Engl J Med. 1982 Jul 1;307(1):7–13. doi: 10.1056/NEJM198207013070102. [DOI] [PubMed] [Google Scholar]
  36. Rosenstein M., Eberlein T. J., Rosenberg S. A. Adoptive immunotherapy of established syngeneic solid tumors: role of T lymphoid subpopulations. J Immunol. 1984 Apr;132(4):2117–2122. [PubMed] [Google Scholar]
  37. Ruscetti S., Linemeyer D., Field J., Troxler D., Scolnick E. Type-specific radioimmunoassays for the gp70s of mink cell focus-inducing murine leukemia viruses: expression of a cross-reacting antigen in cells infected with the Friend strain of the spleen focus-forming virus. J Exp Med. 1978 Sep 1;148(3):654–663. doi: 10.1084/jem.148.3.654. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Shimonkevitz R., Kappler J., Marrack P., Grey H. Antigen recognition by H-2-restricted T cells. I. Cell-free antigen processing. J Exp Med. 1983 Aug 1;158(2):303–316. doi: 10.1084/jem.158.2.303. [DOI] [PMC free article] [PubMed] [Google Scholar]
  39. Walker B. D., Chakrabarti S., Moss B., Paradis T. J., Flynn T., Durno A. G., Blumberg R. S., Kaplan J. C., Hirsch M. S., Schooley R. T. HIV-specific cytotoxic T lymphocytes in seropositive individuals. Nature. 1987 Jul 23;328(6128):345–348. doi: 10.1038/328345a0. [DOI] [PubMed] [Google Scholar]
  40. Zarling J. M., Eichberg J. W., Moran P. A., McClure J., Sridhar P., Hu S. L. Proliferative and cytotoxic T cells to AIDS virus glycoproteins in chimpanzees immunized with a recombinant vaccinia virus expressing AIDS virus envelope glycoproteins. J Immunol. 1987 Aug 15;139(4):988–990. [PubMed] [Google Scholar]
  41. Zarling J. M., Morton W., Moran P. A., McClure J., Kosowski S. G., Hu S. L. T-cell responses to human AIDS virus in macaques immunized with recombinant vaccinia viruses. 1986 Sep 25-Oct 1Nature. 323(6086):344–346. doi: 10.1038/323344a0. [DOI] [PubMed] [Google Scholar]

Articles from The Journal of Experimental Medicine are provided here courtesy of The Rockefeller University Press

RESOURCES